Mpox (Monkeypox) Vaccine: Eligibility, Schedule & Key Facts

JYNNEOS (Modified Vaccinia Ankara-BN) is the primary vaccine for mpox prevention. It's a non-replicating, two-dose series with favorable safety.

Who Should Get Vaccinated (CDC/WHO Guidance)

  • Post-Exposure Prophylaxis (PEP): Known close contact with confirmed case – ideally ≤4 days, up to 14 days.
  • Pre-Exposure Prophylaxis (PrEP):
    • Gay, bisexual, other MSM, transgender/nonbinary persons with multiple/anonymous partners in past 6 months.
    • Sex workers, partners of above.
    • Lab workers handling orthopoxviruses.
    • Immunocompromised (HIV CD4 <200, chemo, immunosuppressants) – shared decision-making.
    • Travelers to endemic areas with anticipated high-risk exposure.

Vaccine Details

  • Schedule: 2 doses, 28 days apart (0.5 mL SC). Immunocompromised: 3-dose series (0, 28, 56 days).
  • Protection Timeline: Peak ~2 weeks after dose 2; some protection from day 10–14 post dose 1.
  • Efficacy: ~75–85% after 2 doses (observational); reduces severity if breakthrough.
  • Side Effects: Injection site pain/redness (80%), fatigue, headache, myalgia, fever (≤10%). Rare: anaphylaxis.
  • Contraindications: Severe allergy to vaccine components (gentamicin, ciprofloxacin, egg protein). Not contraindicated in pregnancy/breastfeeding if risk outweighs theoretical concern.

Access & Cost

  • Public health clinics, sexual health centers, pharmacies, some PCPs.
  • Free via US government supply (while available); otherwise billed to insurance.

Check local health department for current eligibility and walk-in sites. Vaccination + risk reduction (partner reduction, barrier use) = best protection.

Viral Infections - Related Articles